甘李药业(603087.SH)签订不低于30亿元供应框架协议

Core Viewpoint - The company has signed a technology transfer and supply agreement with Fundação Oswaldo Cruz-Bio-Manguinhos (FZ) and BIOMM S.A. for the Brazil Production Development Partnership (PDP) project, which is expected to positively impact its financial performance in 2025 and beyond [1] Group 1 - The company signed a technology transfer and supply agreement involving insulin glargine technology transfer and the supply of active pharmaceutical ingredients and injection solutions [1] - The supply framework agreement with BIOMM is valued at no less than 3 billion RMB (including tax), with the final amount based on actual orders [1] - The contracts are part of the company's routine operations and align with its strategic development direction, potentially enhancing overall profitability [1]